J&J, Gilead hepatitis C drugs face FDA review panels in October
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and Gilead Sciences face back to back October meetings of US FDA advisers who will consider the merits of the companies’ next-generation hepatitis C treatments.